文献速递心脑血管急症重症综合管理与镇静镇痛

脑出血住院患者伴与不伴脑淀粉样血管病的神经共病患病率及长期结局

Prevalence of Concomitant Neurological Disorders and Long-Term Outcome of Patients Hospitalized for Intracerebral Hemorrhage with Versus without Cerebral Amyloid Angiopathy.
PubMed 文献 · Neurocrit Care · 2023-05-31
一句话结论因脑出血住院患者中,伴脑淀粉样血管病者1年全因死亡率更低,但新诊断癫痫和痴呆的风险是不伴者的2-3倍。

该回顾性队列研究利用TriNetX健康研究网络,纳入年龄≥55岁因脑出血住院的成人患者,按是否伴脑淀粉样血管病诊断分层。共纳入1757例伴脑淀粉样血管病的脑出血患者和53364例不伴脑淀粉样血管病的脑出血患者。倾向性评分匹配后,伴脑淀粉样血管病者1年全因死亡率更低(27% vs 32%;HR 0.80;95%CI 0.71-0.90),但新诊断癫痫、阿尔茨海默病、轻度认知障碍、血管性痴呆和未特指痴呆的风险均更高。提示对脑出血伴脑淀粉样血管病患者,除急性期救治外,需关注癫痫和认知障碍的长期监测。

要点

  • 伴脑淀粉样血管病的脑出血患者1年全因死亡率更低(27% vs 32%;HR 0.80;95%CI 0.71-0.90)。
  • 伴脑淀粉样血管病者新诊断癫痫风险更高(18% vs 11%;HR 1.70;95%CI 1.40-2.06)。
  • 伴脑淀粉样血管病者新诊断阿尔茨海默病风险更高(6% vs 2%;HR 2.62;95%CI 1.80-3.80)。
  • 伴脑淀粉样血管病者新诊断血管性痴呆风险更高(7% vs 4%;HR 1.92;95%CI 1.41-2.62)。
  • 伴脑淀粉样血管病者新诊断未特指痴呆风险更高(16% vs 9%;HR 1.70;95%CI 1.39-2.08)。

适用人群与场景

  • 年龄≥55岁因脑出血住院的成人患者,来自TriNetX健康研究网络,按是否伴脑淀粉样血管病诊断分层。

研究设计与关键结果

  • 回顾性队列观察研究,纳入1757例伴脑淀粉样血管病的脑出血患者和53364例不伴脑淀粉样血管病的脑出血患者。
  • 伴脑淀粉样血管病者年龄更大(74.1±7.5岁 vs 69.8±8.8岁,p≤0.001)。
  • 伴脑淀粉样血管病者基线脑梗死患病率30% vs 20%,非创伤性脑出血36% vs 7%,非创伤性蛛网膜下腔出血14% vs 5%,癫痫11% vs 6%,阿尔茨海默病5% vs 2%,均p<0.001。
  • 倾向性评分匹配后两组各纳入1746例;伴脑淀粉样血管病者1年全因死亡率更低(479例[27%] vs 563例[32%];HR 0.80;95%CI 0.71-0.90)。
  • 匹配队列中新诊断癫痫风险更高(280例[18%] vs 167例[11%];HR 1.70;95%CI 1.40-2.06)。
  • 新诊断阿尔茨海默病风险更高(101例[6%] vs 38例[2%];HR 2.62;95%CI 1.80-3.80)。
  • 新诊断轻度认知障碍风险更高(85例[5%] vs 35例[2%];HR 2.39;95%CI 1.61-3.54)。
  • 新诊断血管性痴呆风险更高(117例[7%] vs 60例[4%];HR 1.92;95%CI 1.41-2.62);新诊断未特指痴呆风险更高(245例[16%] vs 150例[9%];HR 1.70;95%CI 1.39-2.08)。

证据类型、等级与局限

  • 证据类型:回顾性队列观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对因脑出血住院且伴脑淀粉样血管病的患者,除急性期救治外,作者认为需关注1年内新发癫痫和痴呆的风险,伴脑淀粉样血管病者新诊断癫痫和痴呆的风险是不伴者的2-3倍。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with intracerebral hemorrhage (ICH) related to cerebral amyloid angiopathy (CAA) are at increased risk of developing epilepsy and cognitive disorders such as Alzheimer's disease (AD), mild cognitive impairment (MCI), and vascular dementia. In a retrospective cohort observation study of patients hospitalized for ICH with CAA versus ICH without CAA, we evaluated the prevalence of neurological comorbidities at admission and the risk of new diagnosis of epilepsy, relevant cognitive disorders, and mortality at 1 year.

METHODS: In the TriNetX health research network, adult patients aged ≥ 55 years hospitalized with a diagnosis of ICH were stratified based on presence or absence of concomitant CAA diagnosis. Demographics and medical comorbidities were compared by using χ2 test and Student's t-test. After 1:1 propensity score matching, 1-year survival was assessed with Kaplan-Meier curves. The 1-year risk of new diagnosis of epilepsy, AD, MCI, vascular dementia, and dementia unspecified was assessed with Cox proportional hazards estimate.

RESULTS: The study included a total of 1757 patients with ICH and CAA and 53,364 patients with ICH without CAA. Patients with CAA were older compared with those without CAA (74.1 ± 7.5 vs. 69.8 ± 8.8 years, p ≤ 0.001). Compared with ICH without CAA, patients with ICH and CAA had higher baseline prevalence of cerebral infarction (30% vs. 20%), nontraumatic ICH (36% vs. 7%), nontraumatic subarachnoid hemorrhage (14% vs. 5%), epilepsy (11% vs. 6%), and AD (5% vs. 2%) with significance at p < 0.001. After propensity score matching, a total of 1746 patients were included in both cohorts. In the matched cohorts, compared with patients with ICH without CAA, patients with ICH and CAA had lower 1-year all-cause mortality (479 [27%] vs. 563 [32%]; hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.71-0.90) and higher risk of new diagnosis of epilepsy (280 [18%] vs. 167 [11%]; HR 1.70; 95% CI 1.40-2.06), AD (101 [6%] vs. 38 [2%]; HR 2.62; 95% CI 1.80-3.80), MCI (85 [5%] vs. 35 [2%]; HR 2.39; 95% CI 1.61-3.54), vascular dementia (117 [7%] vs. 60 [4%]; HR 1.92; 95% CI 1.41-2.62), and dementia unspecified (245 [16%] vs. 150 [9%]; HR 1.70; 95% CI 1.39-2.08).

CONCLUSIONS: Among patients admitted for ICH, patients with CAA have lower mortality but have 2-3 times more risk of diagnosis of epilepsy and dementia at 1 year, compared with those without CAA.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Nagaraja N, Ballur Narayana Reddy V. Prevalence of Concomitant Neurological Disorders and Long-Term Outcome of Patients Hospitalized for Intracerebral Hemorrhage with Versus without Cerebral Amyloid Angiopathy. Neurocrit Care. 2023. PMID: 37258986. doi:10.1007/s12028-023-01753-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。